AP Biosciences and Tasly Amend Collaboration to Accelerate Global Development of Dual-Target Cancer Therapy AP505
核心洞察
AP Biosciences (搜索) and Tasly Pharmaceutical have finalized an amended collaboration agreement to support global out-licensing of AP505 (B1962), a bispecific antibody targeting both PD-L1 (搜索) and VEGF (搜索) pathways.
The dual-target therapy has completed Phase 1 trials and is currently in Phase 2 evaluation for advanced solid tumors, showing promise for treatment-resistant cancers including hepatocellular carcinoma.
Under the amended terms, Tasly will provide clinical data, regulatory materials, and drug supply to support AP Biosciences (搜索)' efforts to engage international partners outside China, Hong Kong, and Macau.
AP Biosciences (搜索), a Taiwan-based clinical-stage biopharmaceutical company, announced the finalization of an amended collaboration agreement with Tasly Pharmaceutical Group (搜索) Co. Ltd. on March 30, 2026, establishing a framework for global out-licensing of AP505 (B1962) outside the original agreement's designated territory of mainland China, Hong Kong, and Macau.
Dual-Pathway Cancer Therapy Advances Through Clinical Development
AP505 (B1962) represents a novel approach to cancer treatment as a bispecific antibody engineered to simultaneously target programmed cell death ligand-1 (PD-L1 (搜索)) and vascular endothelial growth factor (VEGF (搜索)). This dual-targeting mechanism aims to both release immune suppression on T cells and inhibit tumor-driven angiogenesis, potentially enhancing anti-tumor activity compared to conventional monotherapies.
The therapy has completed Phase 1 clinical studies and is currently being evaluated in Phase 2 trials led by Tasly for advanced solid tumors. The bispecific antibody's symmetric IgG-based fusion protein structure increases manufacturability and stability while enabling purification using standard monoclonal antibody processes.
Strategic Framework for Global Expansion
"This amendment reflects the shared commitment between AP Biosciences (搜索) and Tasly to accelerate the development and commercialization of AP505 (B1962) for patients globally," said Jeng Her, Ph.D., Founder and Chief Executive Officer of AP Biosciences. "By establishing clear and rapid pathways for technology transfer, clinical data sharing, and clinical supply, this agreement enhances our readiness to engage potential partners and progress AP505 (B1962) toward ex-Territory clinical development."
Under the amended terms, Tasly will support AP Biosciences (搜索)' global development and partnering efforts by providing relevant clinical data, regulatory materials, and clinical supply for studies outside the original territory on a revenue-sharing basis. The agreement also establishes a framework for technology transfer and collaboration with potential third-party partners in international markets.
Addressing Treatment-Resistant Cancer Indications
The dual-pathway mechanism of AP505 (B1962) is designed to address major unmet needs in indications such as hepatocellular carcinoma and pMMR colorectal cancer, where single-agent immunotherapies have shown limited efficacy. The collaboration structure pairs Tasly's proven clinical development efficiency within their designated territory with AP Biosciences (搜索)' global development and partnering strategy.
The amended deal is designed to accelerate AP505 (B1962)'s continued advancement while maximizing its value both within and outside the original territory in international markets. Locust Walk Partners (搜索), LLC, served as the lead financial advisor for the collaboration agreement amendment.
AP Biosciences (搜索) applies its proprietary Omni-Mab and T-cube platforms to pioneer next-generation bispecific antibodies that activate the immune system precisely where needed, targeting both established and treatment-resistant cancers.